Sarepta Therapeutics has entered into a long-term strategic manufacturing partnership with Paragon Bioservices, which will provide Sarepta access to additional commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as a manufacturing platform for future gene therapy programs, such as Limb-girdle muscular dystrophy (LGMD). "We are rapidly building a formidable gene therapy engine, the hallmark of which will be the establishment of our Gene Therapy Center of Excellence in Columbus, OH. Therefore, it is incumbent upon us to ensure that our ambition is matched with a sophisticated, robust and scalable manufacturing approach that can accelerate a steady stream of gene therapies to treat life-robbing genetic diseases for the near and long-term," said Doug Ingram, president and chief executive officer, Sarepta.